Effect of different doses of oral Furosemide on Urine volume in peritoNeal Dialysis patients

Phase 3

• Conditions: End- stage renal disease patients performing peritoneal dialysisResidual renal function; Peritoneal dialysis

• Registration Number: TCTR20200723004
• Lead Sponsor: Division of nephrology

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2020-07-23
• Study Completion: 2021-01-29
• Last Update Posted: 19 August 2024

Recruitment & Eligibility

• Status: Pending (Not yet recruiting)
• Sex: All
• Target Recruitment: 100

Inclusion Criteria

1. Adults aged 18â€80 years old
2. ESRD patients treated with PD at least 1 month
3. No history of PD related peritonitis within 1 month
4. No history of membrane failure or ultrafiltration failure

Exclusion Criteria

1. Patients with hypotension (mean arterial blood pressure < 65 mmHg) or orthostatic hypotension
2. Patients with clinical of fluid overload within 1 month exp. heart failure, generalized edema, pleural effusion or ascites from physical examination or imaging
3. Patients who use less than 125 mg or more than 1,000 mg per day of oral furosemide
4. Serum potassium less than 3.0 mEq/L
5. Serum albumin less than 2.5 g/dL
6. Patients using other diuretic drugs
7. Patients with contraindication for furosemide
8. Patients who have 24-hour urine volume less than 100 ml after the run-in phase of this study

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
24-hour urine volume at 1 month after receiving intervention milliltre

Secondary Outcome Measures

Name	Time	Method
rinary sodium excretion at 1 month after receiving intervention measure sodium in 24-hour urine ,Renal clearance by using creatinine clearance and Kt/V of urea at 1 month after receiving intervention Calculate from measured creatinine and urea from blood and urine